secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEKTAR THERAPEUTICS (NKTR)
CIK:        0000906709
Form:       8-K
Filed at:   2026-06-05T20:30:15+00:00
Accession:  0001213900-26-065845
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Nektar Therapeutics holds 2026 annual meeting; all four proposals approved
--------------------------------------------------------------------------

- Howard W. Robin elected director with 13,164,879 for, 4,975,288 against, 286,175 abstain; broker non-votes 4,588,835.
- Equity plan amendment to increase authorized shares by 3,000,000 approved: 13,160,661 for, 4,902,925 against, 362,756 abstain.
- Ratification of Ernst & Young as auditor for FY 2026 approved: 22,591,556 for, 118,592 against, 305,029 abstain.
- Advisory say-on-pay resolution approved: 18,154,226 for, 161,005 against, 111,111 abstain; broker non-votes 4,588,835.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/906709/000121390026065845/0001213900-26-065845-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/906709/000121390026065845/ea0293744-8k_nektar.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-065845

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer